BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7472782)

  • 41. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus.
    Soong R; Knowles S; Hammond IG; Michael C; Iacopetta BJ
    Cancer Detect Prev; 1999; 23(1):8-12. PubMed ID: 9892985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
    de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
    Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
    Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
    Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus).
    Sprogøe-Jakobsen S; Hølund B
    APMIS; 1996 Oct; 104(10):705-8. PubMed ID: 8980620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. p53 protein overexpression in smooth muscle tumors of the uterus.
    Niemann TH; Raab SS; Lenel JC; Rodgers JR; Robinson RA
    Hum Pathol; 1995 Apr; 26(4):375-9. PubMed ID: 7705814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
    Croce S; Chibon F
    Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
    Ip PP; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
    Fernandez-Flores A; Monteagudo C
    Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
    Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
    Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
    Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
    Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DOG1 immunoreactivity in uterine leiomyosarcomas.
    Sah SP; McCluggage WG
    J Clin Pathol; 2013 Jan; 66(1):40-3. PubMed ID: 23038686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of immunohistochemistry-laser microdissection-PCR technique in detecting p53 gene mutation in paraffin sections of gastric cancer].
    Xu JH; Chen LR; Wang HJ; Yao LF
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):342-5. PubMed ID: 15363320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
    Fadare O; Renshaw IL; Liang SX
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
    Deng ZJ; Guo LN
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
    Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
    Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 gene mutation and expression in naevi and melanomas.
    Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
    Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.